DEVELOPMENT AND OPTIMIZATION OF TAZAROTENE LOADED SOLID LIPID NANOPARTICLES FOR TOPICAL DELIVERY by RAJKUMAR ALAND et al.
Vol 12, Issue 10, 2019
Online - 2455-3891 
Print - 0974-2441
DEVELOPMENT AND OPTIMIZATION OF TAZAROTENE LOADED SOLID LIPID 
NANOPARTICLES FOR TOPICAL DELIVERY
RAJKUMAR ALAND1*, GANESAN M2, RAJESWARA RAO P3
1Department of  Pharmacy, Jawaharlal Nehru Technological University, Kakinada, Andhra Pradesh, India. 2Dr. Reddy’s Laboratories 
Limited, Hyderabad, Telangana, India. 3Department of  Pharmacy, Andhra University, Visakhapatnam, Andhra Pradesh, India. 
Email: raj_aland@rediffmail.com
Received: 29 December 2018, Revised and Accepted: 27 July 2019
ABSTRACT
Objective: Psoriasis is an unswervingly recurring, inflammatory, autoimmune disorder of the skin, disturbing about 2–5% of the world population. 
The main objective for this investigation is to develop and optimize the solid lipid nanoparticles (SLN) formulation of tazarotene for effective drug 
delivery.
Methods: Tazarotene SLNs were fabricated by hot homogenization followed by the ultrasonication using Taguchi’s orthogonal array with eight 
parameters that could affect the particle size and entrapment efficiency (EE). In view of the outcomes from the examinations of the responses acquired 
from Taguchi design, three diverse independent variables including sonication time (s), lipid to drug ratio (w/w), and surfactant concentration (%) 
were carefully chosen for further investigation utilizing central composite design. The lipid dynasan-116, surfactant poloxamer-188, and cosurfactant 
egg lecithin resulted in better percent drug loading and evaluated for particle size, drug EE, zeta potential, in vitro drug release, and stability.
Results: The prepared nanoformulations were evaluated for different parameters and found to be in an acceptable range. In vitro drug release of 
optimized SLN formulation (F1) was found to be 98.12±1.52%, whereas pure drug release was 42.12 after 60 min, and the major mechanism of drug 
release follows zero-order kinetics release data for optimized formulation (F1) with non-Fickian (anomalous) with a strong correlation coefficient 
(R2=0.98598) of Korsmeyer-Peppas model. Transmission electron microscopy analysis has demonstrated the presence of individual nanoparticles 
in spherical shape, and the results were also compatible with particle size measurements. The drug content of tazarotene gel formulation was 
found to 98.96±0.021%, and the viscosity of gel formulation at 5 rpm was found to be 5.98×103±0.34×103 cp. The release rate (flux) of tazarotene 
across the membrane and expunged skin diverges pointedly, which specifies the barrier nature of skin. The flux value for SLN based gel formulation 
(193.454±4.324 μg/cm2/h) was found to be higher than that for marketed gel (116.345±2.238 μg/cm2/h). The higher flux and Kp values of SLN based 
gel suggest that it might be able to enter the skin easily as compared with marketed gel with an advantage of low interfacial tension of the emulsifier 
film that ensures an excellent contact to the skin.
Conclusion: From the obtained results, the topically oriented SLN-based gel formulation of tazarotene could be useful in providing effective and site-
specific psoriasis treatment.
Keywords: Tazarotene, Psoriasis, Taguchi design, Solid lipid nanoparticles, Topical gel, Flux.
INTRODUCTION
Solid lipid nanoparticles (SLN) fascinated the researchers during 
the years in view of different advantages over other colloidal 
drug delivery systems such as biocompatibility, high drug loading 
(DL) capacity, possibility of controlled drug release, enhanced 
bioavailability, improved protection of drug against metabolism, 
increased drug stability, feasibility of bulk manufacturing and 
sterilization, less variability in release mechanisms and their 
kinetics, potential for improved permeability due to lipid and 
surfactant contents, and ligand-mediated or passive targeting due 
to their small size through oral, ocular, nasal, dermal, parenteral, 
and pulmonary routes of administration [1-3]. SLNs are the quickly 
developing field of nanotechnology with a few potential applications 
in drug delivery and research. Because of their one of a kind, size-
dependent properties, lipid nanoparticles bid the opportunity to 
develop novel therapeutics [4]. SLNs are used as topical vehicle 
because of their intrinsic occlusive properties that form a film on 
skin surface, reducing transepidermal water loss. The increasing of 
the water content improves the appearance of healthy human skin 
and boosts the penetration of active through the skin; moreover, the 
reduced particle size improves surface area and facilitates contact of 
encapsulated drugs with the stratum corneum [5].
Psoriasis is a chronic T-cell mediated autoimmune inflammatory skin 
disease with reverting events of inflammation and hyperkeratosis on 
the skin [6-10]. At present, many researchers attend to development of 
innovative skin drug delivery systems to improve skin penetration of 
conventional drugs leading to a reduction of the administered dose and 
therefore their side effects [11].
Tazarotene, is 6-[2-(4,4-dimethylthiochroman- 6-yl)ethynyl] ethyl 
nicotinate, a member of a new generation of receptor-selective 
synthetic retinoids, indicated in the mild to moderate plaque psoriasis 
disease, acne vulgaris, and photoaging. Dermal safety studies have 
specified that tazarotene did not demonstrate photoallergic or 
phototoxic potential [12]. However, the course of treatment which is 
usually prolonged (weeks or months) may lead to adverse reactions 
such as pruritus, burning/stinging, and erythema in a significant subset 
of users. These may often result in the interruption or discontinuation 
of the treatment regimen. Further, extremely low solubility limits 
tazarotene incorporation into an acceptable vehicle and its tolerability 
results in either discontinuation of treatment or poor compliance in 
patients [13,14].
This current work demonstrates the formulation of tazarotene SLN 
employing hot homogenization followed by ultrasonication method and 
© 2019 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
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central composite design (CCD) comprising 3-factor, 3-level method 
was utilized for the optimization of the prepared formulations.
MATERIALS AND METHODS
Materials
Tazarotene was a kind gift from Dr. Reddy’s Laboratory Ltd., 
Hyderabad, India. Tristearin (dynasan-118), tripalmitin (dynasan116), 
and trimyristin (dynasan-114) were procured from Sigma-Aldrich 
Chemicals, Hyderabad, India. Poloxamer-188 and Egg Lecithin were 
gifted by Aurobindo Labs, India. All other chemicals and solvents were 
of analytical grade and were used without further purification.
Dialysis Bag (Molecular weight cut off 10 kDa) was procured from 
HiMedia Pvt., Ltd., Trehalose dihydrate was acquired from Sigma 
Chemicals Co. All other chemicals used were of analytical grade or 
spectroscopic grade.
Characterization by differential scanning calorimetric (DSC)
Accurately weighed amount (5 mg) of drug sample to be analyzed was 
taken in the pierced DSC aluminum pan and scanned in the temperature 
range of 50–230°C. The heating rate was 20°C/min and thermogram of 
drug was obtained.
Preparation of tazarotene loaded SLN
Tazarotene loaded SLNs were fabricated by hot homogenization 
method followed by the ultrasonication [15,16]. In a 5 ml of 1:1 binary 
mixture of methanol and chloroform, tazarotene, egg lecithin, and lipid 
were dissolved. Organic solvents were completely removed using a rota 
evaporator. By heating to 5°C above the melting point of the lipid, the 
drug embedded lipid layer was molten. The aqueous phase was made by 
dissolving poloxamer 188 in double-distilled water and heated to same 
temperature (based on lipid melting point) of oil phase. Hot aqueous 
phase was added to the oil phase and homogenization was carried out 
(at 12000 rpm) using homogenizer for 4 min. The coarse hot oil in water 
emulsion so obtained was ultrasonicated for 20 min by employing a 12 
T probe sonicator. Consequential, hot nanoemulsion allowed to cool to 
room temperature that finally produced the tazarotene loaded SLN.
The statistical experimental design can determine the effect of the 
factors on characterization properties and the optimal conditions of 
factors [17,18].
Screening study
In the first step, a Taguchi design with seven variables at two different 
levels was utilized to determine the factors affecting particle size and 
entrapment efficiency (EE) [19].
Taguchi method
Two major tools used in the Taguchi method are the orthogonal arrays 
and ANOVA and the signal-to-noise ratio (S/N). ANOVA is a matrix of 
numbers arranged in rows and columns. Each row represents the 
level of factors in each run, and each column represents a specific level 
for a factor that can be changed for each run. S/N implies the quality, 
and the main objective of the Taguchi experiment is to find the best 
level for each operational parameter so as to minimize (or maximize) 
S/N [20-22].
Experimental parameters
The Stat-Ease Design Expert® software V8.0.1 was used for regression 
and graphical analysis of the obtained data. For our experiments, 
we considered eight parameters (surfactant type, type of lipid, 
surfactant concentration, cosurfactant concentration, lipid-to-drug 
ratio, chloroform-methanol ratio, organic-aqueous phase ratio, and 
sonication time). Taguchi’s orthogonal array is chosen with eight 
parameters that could affect the EE and particle size. The levels of each 
operating parameter for the preparation of SLN formulation equivalent 
to 100 mg of tazarotene are listed in Table 1. Here, L18 (21×37) 
represents 18 experiments with one 2-level factor and seven 3-level 
factors (Table 2).
The optimum values of the significant factors were determined 
using response surface methodology. The impact of the experimental 
variables such as EE concentration of lipid, concentration of surfactant 
and sonication time on the particle size, and percent DL of nanoparticles 
was evaluated by the RSM, based on CCD [23].
CCD
In view of the outcomes from the examinations of the responses 
acquired from Taguchi design, three diverse independent variables 
including sonication time(s), lipid-to-drug ratio (w/w), and surfactant 
concentration (%) were carefully chosen for further investigation 
utilizing CCD. The range of level of each independent variable was set 
according to the preliminary experiments (Table 3).
On the basis of the CCD model provided by Stat-Ease Design Expert® 
software V8.0.1, 19 model experiments were randomly arranged. 
The experiments were conducted as for the design and the obtained 
responses for the dependent variables Particle size-Y1, EE-Y2, and 
percent DL-Y3 (Table 4).
Characterization of tazarotene loaded SLN
Mean particle size, polydispersity index, and zeta potential
The mean particle size, polydispersity index, and zeta potential of 
tazarotene nanoparticles were determined by laser light diffractometry 
using zetasizer nanoseries, SM2000K (Malvern Instruments Inc., UK). 
From the prepared SLN dispersion, 100 ml was diluted to 5 ml with 
double distilled water to get optimum kilo counts per second (Kcps) of 
50–200 for measurements. All measurements were carried out at 25°C 
and performed in triplicate.
Lyophilization of SLNs
Lyophilization technique was employed for the enhancement of 
stability of SLNs. The drug-loaded SLNs containing 10% w/v tazarotene 
were prepared and set aside for overnight at −40°C in deep freezer. The 
frozen samples were subjected to vacuum freeze-drying process for 
about 48 h to get powdered lyophilized product.
EE and percent DL determination
EE was determined by measuring the concentration of unentrapped 
free drug in an aqueous medium containing either PVA or PLX. Plain 
SLN without drug was used as blank sample and centrifuged in the 
same manner.
Table 1: List of variables and their levels used in L18 Taguchi orthogonal array design
Factor Name Units Type Low actual High actual Level
A Surfactant type Categoric PVA PLX-188 2
B Lipid type Categoric D-114 D-118 3
C Surfactant concentration mg Categoric 100 200 3
D Cosurfactant concentration mg Categoric 100 200 3
E Lipid/Drug Categoric 10 30 3
F Chloroform: methanol v/v Categoric 0.5:1.5 1.5:0.5 3
G Organic phase: aqueous phase v/v Categoric 0.5:1.5 1.5:0.5 3
H Sonication time sec Categoric 120 240 3
PVA: Polyvinyl alcohol, PLX-188: Poloxomer-188, D-114: Dynasan-114, D-116: Dynasan-116, D-118: Dynasan-118
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Surface morphology by transmission electron microscopy (TEM)
The morphology of the tazarotene loaded nanoformulation was 
determined by TEM (JEM-2000 EXII; JEOL, Tokyo, Japan) [24].
Solid state characterization
DSC studies
DSC analysis of tazarotene, dynasan-116, poloxamer-188, egg lecithin 
and physical mixtures (PM in 1:1 ratio), and lyophilized tazarotene 
nanoparticles was performed using a Perkin Elmer DSC/7 DSC (Perkin-
Elmer, CT-USA).
Powder X-ray diffraction (PXRD) studies
The Powder XRD patterns of tazarotene, dynasan-116, poloxamer-188, 
egg lecithin, and physical mixtures (PM in 1:1 ratio), and lyophilized 
tazarotene nanoparticles were determined by means of X-ray 
diffractometer (Bruker D8 Advance). The assessment was conducted 
under the following circumstances: Irradiation with monochromatized 
Cu Kα radiation (λ=1.542 A°), current (30 mA), and voltage (40 kV) 
from 2° to 40° at 2θ angle.
In vitro drug release studies
In vitro release studies were conducted by utilizing dialysis bag method 
with phosphate-buffered saline (pH 7.4) as dissolution medium at 
37°C with the speed of 50 rpm. At predetermined time points, 3ml of 
dissolution medium was taken and filtered as described above and 
analyzed by UV-visible spectrophotometer at 246 nm. The removed 
volume was replaced with the same volume of phosphate-buffered 
saline (pH 7.4).
Drug release kinetics
To explicate the manner and mechanism of drug release, the data 
from the in vitro release experiments were fitted into various kinetic 
models, such as Korsmeyer-Peppas model, Higuchi’s model, first-order, 
and zero-order. Curve fitting method was employed to determine the 
release data from the nanoformulation.
Stability studies
Stability of tazarotene nanoparticles suspension in screw-capped 
glass vials was evaluated over a period of 60 days. Six samples were 
divided into two groups and stored at 25°C and 4°C. Drug leakage from 
nanoparticles and mean particle size of the samples was determined at 
the end of 1, 7, 15, 30, 45, 60, and 90 days.
Preparation of tazarotene loaded SLN gel
The tazarotene loaded SLN gel formulation was prepared by dispersing 
required quantity of Carbopol 934 P (1% w/w) in a small quantity 
of distilled water and allowing to hydrate for 4–5 h. To the aqueous 
dispersion, glycerol (30% w/w) and propylene glycol (10% w/w) 
were added later. Inclusion of air was avoided by addition of 0.5 ml 


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 3: List of dependent and independent variables and their 
levels used in central composite design
Independent variables Levels
Variable Name Units −1 +1 −α +α
A Surfactant 
concentration
Mg 100 200 65.91 234.09
B Lipid-to-drug 
ratio
v/v 10 30 3.18 36.82
C Sonication time Sec 120 240 79.09 280.91
Dependent variable Goal
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equivalent to 150 mg of the drug was incorporated into the gel under 
gentle stirring. Finally, rest of the water (58.85% w/w) was added to 
make up the volume of dispersion up to 100% w/w [25].
Characterization of SLN based gel of tazarotene
Characterization of SLN base gel of tazarotene was done by 
determination of drug content by UV spectrophotometric method, 
determination of spreadability of the gel [26], determination of pH using 
digital pH meter (HI 98107, Hanna Instruments, India), and rheological 
studies on the microemulsion-based gel using Brookfield Viscometer 
LVDV - IIIU (Brookfield Engineering LABS, Stoughton, USA) [27].
RESULTS AND DISCUSSION
DSC thermogram
Thermogram of tazarotene exhibited sharp characteristic endothermic 
peaks at 104°C, confirming the identity of the drug (Fig. 1).
Analysis of experimental data
Experimental data were analyzed using S/N ratio and ANOVA. Based 
on the results of the ANOVA and S/N ratio, finest parameter settings 
for improved accuracy were found and substantiated experimentally. 
Regression models were established to attain the compensation factor 
for any set of process parameters [28]. The experimental results from 
analysis of variance are found to be significant and the values of R2, 
predicted R2, adjusted R2, and adequate precision for each response are 
shown in Table 5.
Effect of process parameters on the particle size
The results of the statistical analysis revealed that changing the lipid-
to-drug ratio from 10:1 to 30:1 has shown an increase in particle size 
(Fig. 2a), which could be due to higher concentrations of lipid resulted 
in increased viscosity of the solution, which thereby decreases the 
shear capacity of the stirrer and inversely affects the particle size.
Fig. 1: Differential scanning calorimetric thermogram of tazarotene pure drug
Table 4: Central composite design with observed responses
Run Surfactant 
concentration (mg)
Lipid to drug 
ratio (w/w)
Sonication time (s) Particle size (nm) Entrapment 
efficiency (%)
Percent drug loading (%)
1 150 20 180 115.12 84.2 11.62
2 150 20 180 114.56 83.6 11.34
3 150 20 79.09243 128.36 85.4 11.87
4 100 30 120 153.72 86.12 11.34
5 65.91036 20 180 134.76 91.52 10.76
6 150 20 280.9076 155.63 83.06 10.96
7 150 20 180 116.36 82.86 11.82
8 200 10 120 104.35 90.62 13.42
9 234.0896 20 180 131.35 92.32 12.34
10 200 30 120 154.48 89.34 11.86
11 150 20 180 114.56 83.45 11.67
12 200 10 240 120.32 83.58 10.92
13 150 36.81793 180 169.72 90.23 10.46
14 200 30 240 162.67 89.56 11.22
15 150 3.182072 180 86.22 84.29 9.5
16 100 10 120 104.78 88.12 12.34
17 150 20 180 114.92 84.17 11.76
18 150 20 180 115.12 83.58 11.74
19 100 10 240 117.44 84.67 10.92
20 100 30 240 165.72 91.86 9.82
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Fig. 2b revealed the effect of sonication time on particle size. As the 
sonication time is increased, it resulted in decreased particle size. A little 
interactive effect was observed between E (lipid to drug ratio) and H 
(Chloroform: methanol) as evidenced from 3D surface plot (Fig. 3).
Effect of process parameters on EE
The outcomes of the statistical analysis exposed that the type of 
surfactant has a clear noteworthy impact on EE (Fig. 4). The surfactant 
poloxamer-188 has shown better EE compared to polyvinyl alcohol.
Effect of process parameters on percent DL
The surfactant poloxamer-188 resulted in better percent DL compared 
to polyvinyl alcohol (Fig. 5). The lipid dynasan-116 has resulted in better 
DL compared to other lipids (Fig. 6). A significant interactive effect was 
observed between A (surfactant type) and B (lipid type) as evidenced 
from 3D surface plot (Fig. 7). Similarly, a significant interactive effect 
was detected between B (lipid type) and C (surfactant concentration) 
as evidenced from 3D surface plot (Fig. 8).
CCD analysis
Analysis of particle size
Twenty experiments are required for the response surface methodology 
founded on the CCD when there are three factors at four levels each. The 
theoretical (predicted) values and the observed values of the response 
particle size (Y1) were in reasonably good agreement. The main effects, 
quadratic effects, and interaction effects of surfactant concentration 
(A), lipid to drug ratio (B), and sonication time (C) on particle size (Y1) 
are represented in Fig. 9. As the lipid-to-drug ratio increases from 10 
to 30, the particle size of nanoparticles was found to increase from 
86.22 nm to 169.72 nm. Similarly by increasing the sonication time, the 
particle size was moderately increased. The interaction between the 
surfactant concentration (A) and lipid to drug ratio (B) on particle size 
(Y1) at a fixed level of C (180 s) is recorded (Fig. 10).
Analysis for EE
The main effects, quadratic effects, and interaction effects of surfactant 
concentration (A), lipid-to-drug ratio (B), and sonication time (C) on EE 
Fig. 3: 3D surface plot showing the interactive effect of F (Chloroform:methanol) and E (lipid-to-drug ratio) on particle size
Table 5: values of R2, predicted R2, adjusted R2, and adequate 







R-squared 0.9661 0.8397 0.7950
Adjusted R-squared 0.9556 0.8297 0.7511
Predicted R-squared 0.9350 0.7971 0.6612
Adequate precision 27.993 12.947 11.430
Table 6: Optimized values obtained by the constraints applies on Y1, Y2, and Y3
Independent variable Nominal 
values













Concentration of surfactant (A) 200 102.894 90.567 12.355 I 95.57 91.24 11.92
II 91.34 90.63 12.32
Lipid to drug ratio (B) 10 III 94.14 90.78 12.16
Sonication time (C) 120
Fig. 2: Effect of different variables on particle size (a) lipid-to-drug ratio and (b) sonication time
a b
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Fig. 4: Effect of surfactant type (A) on entrapment efficiency (Y2)
Fig. 5: Effect of surfactant type (A) on percent drug loading (Y3)
Fig. 6: Effect of lipid type (B) on percent drug loading (Y3)
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(Y2) (Fig. 11). The figure clearly shows that at surfactant concentration 
(A) has a negative effect on EE (Y2) at low levels. Fig. 12a shows the 
interaction between the surfactant concentration (A) and sonication 
time (C) on EE (Y2) at a fixed level of B (20:1). Fig. 12b shows the 
interaction between the lipid to drug ratio (B) and sonication time (C) 
on EE (Y2) at a fixed level of A (150 mg).
Fig. 7: 3D surface plot showing the Interactive effect of A (surfactant type) and B (lipid type) on percent drug loading
Fig. 8: 3D surface plot showing the interactive effect of B (lipid type) and C (surfactant concentration) on percent drug loading
Fig. 9: Perturbation plot showing the effect of A, B, and C on particle size
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Fig. 10: Response surface plot showing the influence of surfactant concentration and lipid-to-drug ratio on particle size
Fig. 11: Perturbation plot showing the effect of A, B, and C on entrapment efficiency
Fig. 12: (a) Response surface plot showing the influence surfactant concentration and sonication time on entrapment efficiency. 
(b) Response surface plot showing the influence of lipid-to-drug ratio and sonication time on entrapment efficiency
ba
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Analysis for percentage DL
The surfactant concentration (A) has a synergistic effect, and sonication 
time has an antagonistic effect on percent DL. The theoretical 
(predicted) values and the observed values were in reasonably good 
agreement. The perturbation plot showing the effect of A and C on 
percent DL plotted (Fig. 13).
Optimization and confirmation experiments
A numerical optimization technique by utilizing the desirability strategy 
was hired to prepare Tazarotene nanoparticles with the anticipated 
responses. The optimized levels and predicted values of Y1, Y2, and 
Y3 are shown in Table 6. All the prepared formulations were analyzed 
to determine their zeta potential and particle size distribution. The 
mean size of all the formulations was ranging from 91.34±6.8 nm to 
95.57±6.3 nm (Table 7).
Surface morphology by TEM
TEM analysis has demonstrated the existence of individual nanoparticles 
in a spherical shape. Surface morphology resolves the basic function 
of particles, degradation, release of drug from the polymer matrix, 
transport of particles in the body, and internalization of drug. TEM 
results were also compatible with DLS particle size measurements 
(Fig. 14).
DSC studies
The DSC thermogram of pure tazarotene exhibited sharp endothermic peaks 
at 104°C (Fig. 1). The DSC of dynasan-116 displayed a sharp endothermic 
peak at 66.53°C (Fig. 15). The distinctive endothermic peaks of the distinct 
components were evident in the physical mixture (Fig. 16). The peak for 
tazarotene was entirely absent in lyophilized SLN of tazarotene (Fig. 17). 
The absence of an endothermic peak in the nanoparticulate formulations 
resolved that the drug was existing in the amorphous phase and may have 
been homogeneously dispersed in the lipid.
PXRD pattern
From the PXRD results, it was obvious that pure tazarotene displayed 
crystalline nature with representative peaks at 2θ of 13.90°, 15.99°, 
22.68°, and 25.21°. In the physical mixture, the crystalline peaks for 
tazarotene were clearly evident, whereas the nanoformulation showed 
disappearance of the principal peaks of tazarotene, demonstrating its 
existence in an amorphous or molecular dispersion state (Fig. 18).
Drug release study
The in vitro drug release pattern of the drug from the optimized batches 
recorded (Fig. 19). All formulations showed an increase in dissolution 
over pure drug, which showed only ≈42% release after 60 min.
Release kinetics
The results of the release kinetics of the optimized formulation of 
tazarotene SLN (F1) (Figs. 20-23) show that the major mechanism of 
drug release follows zero-order kinetics (Table 8). Further, the n value 
obtained from the Korsmeyer-Peppas plots, i.e., 0.563 indicating non-
Fickian (anomalous) transport thus it projected that delivered its active 
ingredient by coupled diffusion and erosion.
Stability study
The stability study data (Table 9) specifies that no significant difference 
(p < 0.05) was detected in particle size and EE of optimized formulation 
stored at room temperature and refrigerated conditions.
Fig. 13: Perturbation plot showing the effect of A and C on percent drug loading
Table 7: The mean particle size, PDI , zeta potential, entrapment 
efficiency, and % drug loading of optimized formulations
Batch MPS±SD (nm) PDI ZP±SD (mV) % EE±SD % DL±SD
1 95.57±6.3 0.283 −31.8±3.15 91.24 11.92
2 91.34±5.2 0.247 −29.3±4.89 90.63 12.32
3 94.14±6.8 0.240 −28.2±5.14 90.78 12.16
n=3 (p<0.05)
Fig. 14: Transmission electron microscopy image of tazarotene 
nanoparticles
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Formulation of SLN based gel of tazarotene
The gel formulation of tazarotene was made by mixing the swollen 
gel matrix with the oily phase at 2% w/w concentration of Carbopol 
971P NF. The tazarotene content of the gel formulation was found to 
98.96±0.021% w/w of the theoretical value (0.05% w/w). The results 
specify that the processes employed to prepare solid dispersions in this 
study were capable of producing a formulation with uniform drug content. 
Table 8: Release kinetics of optimized formulation of tazarotene SLNs (F1)
Formulation code Zero-order First-order Higuchi Korsmeyer-Peppas
R2 n R2 N R2 n R2 n
F1 0.91306 1.6191 0.90812 0.025 0.96126 13.9388 0.98598 0.563
SLN: Solid lipid nanoparticles
Fig. 15: Differential scanning calorimetric thermogram of dynasan-116
Fig. 16: Differential scanning calorimetric thermogram of tazarotene:dynasan-116 (1:1 physical mixture)
The pH of the gel was found to be 6.8±0.06 indicating that it could result 
in less irritation to the skin. The viscosity of gel formulation at 5 rpm 
was found to be 5.98×103±0.34×103 cp. To assess the skin retention and 
penetration of tazarotene from gel formulation and marketed gel, the 
in vitro permeation ability was determined. The release rate (flux) of 
tazarotene across the membrane and expunged skin diverges pointedly 
(Table 10), which specifies the barrier properties of skin.
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Table 9: Particle size and entrapment efficiency of tazarotene nanoparticles after 90 days of storage at refrigerated and room 
temperature
Temp-erature (°C) Particle size (nm) Entrapment efficiency (%) Release data (% CDR)
0 month 3 months 0 months 3 months 0 months 3 months
30 min 60 min 30 min 60 min
4±1°C 95.57±6.3 96.12±3.26 91.24±1.28 90.83±2.12 71.50±1.27 98.12±1.52 70.56±1.34 97.76±2.15
25±2°C 95.57±6.3 96.27±1.86 91.24±1.28 91.12±1.56 71.50±1.27 98.12±1.52 70.12±1.16 97.82±1.13
n=3 (p<0.05)
Fig. 17: Differential scanning calorimetric thermogram of tazarotene nanoformulation
Fig. 18: X-ray powder diffractograms of tazarotene pure drug (A), physical mixture (B), and optimized formulation F1 (C)
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CONCLUSION
Tazarotene SLNs were prepared by hot homogenization followed by 
the ultrasonication using Taguchi’s design. The lipid dynasan-116, 
surfactant poloxamer-188, and cosurfactant egg lecithin resulted in 
better percent DL and evaluated for particle size, zeta potential, drug 
EE, in vitro drug release, and stability. The prepared nanoformulations 
were evaluated for different parameters and found to be in an acceptable 
Table 10: Flux of tazarotene from SLN based gel formulation
Formulation Flux (μg/cm2/h)
Egg membrane Rat skin
F1 54.354±1.43 193.454±4.324
Marketed formulation 35.366±4.12 116.345±2.238
Control 26.114±1.89 39.654±3.12
Fig. 19: In vitro release of tazarotene from solid lipid nanoparticles
Fig. 20: Plot of zero-order release kinetics of the optimized batch
75
Asian J Pharm Clin Res, Vol 12, Issue 10, 2019, 63-77
 Aland et al. 
Fig. 21: Plot of first-order release kinetics of the optimized batch
Fig. 22: Plot of Higuchi release kinetics of the optimized batch
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range. In vitro drug release of optimized SLN formulation (F1) was found 
to be higher when compared with pure drug and the major mechanism 
of drug release follows zero-order kinetics release data for optimized 
formulation (F1) with non-Fickian (anomalous) of Korsmeyer-Peppas 
model. TEM analysis has demonstrated the presence of individual 
nanoparticles in spherical shape, and the results were also compatible 
with particle size measurements. The drug content of tazarotene 
gel formulation was found to 98.96±0.021%, and the viscosity of 
gel formulation at 5 rpm was found to be 5.98×103±0.34×103 cp. The 
release rate (flux) of tazarotene across the membrane and excised skin 
differs significantly and the flux value for SLN based gel formulation 
(193.454±4.324 μg/cm2/h) was found to be higher than that for 
marketed gel (116.345±2.238 μg/cm2/h). The formulation was stable 
for 3 months. From the obtained results, the topically oriented SLN based 
gel formulation of tazarotene could be useful in providing effective and 
site-specific dermal treatment of psoriasis.
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